Abstract

Active angiogenesis may be assessed by immunohistochemistry using Nestin, a marker of newly formed vessels, combined with Ki67 for proliferating cells. Here, we studied microvascular proliferation by Nestin-Ki67 co-expression in prostate cancer, focusing on relations to quantitative imaging parameters from anatomically matched areas obtained by preoperative mpMRI, clinico-pathological features and prognosis. Tumour slides from 67 patients (radical prostatectomies) were stained for Nestin-Ki67. Proliferative microvessel density (pMVD) and presence of glomeruloid microvascular proliferation (GMP) were recorded. From mpMRI, forward volume transfer constant (Ktrans), reverse volume transfer constant (kep), volume of EES (ve), blood flow, and apparent diffusion coefficient (ADC) were obtained. High pMVD was associated with high blood flow (p = 0.008) and low ADC (p = 0.032). High Ktrans, kep, and blood flow were associated with high Gleason score. High pMVD, GMP, and low ADC were associated with most adverse clinico-pathological factors. Regarding prognosis, high pMVD, Ktrans, kep, and low ADC were associated with reduced biochemical recurrence-free- and metastasis-free survival (p ≤ 0.044) and high blood flow with reduced time to biochemical- and clinical recurrence (p < 0.026). In multivariate analyses however, microvascular proliferation was a stronger predictor compared with blood flow. Indirect, dynamic markers of angiogenesis from mpMRI and direct, static markers of angiogenesis from immunohistochemistry may aid in the stratification and therapy planning of prostate cancer patients.

Details

Title
Microvascular proliferation is associated with high tumour blood flow by mpMRI and disease progression in primary prostate cancer
Author
Børretzen, Astrid 1 ; Reisæter, Lars A. R. 2 ; Ringheim, Anders 3 ; Gravdal, Karsten 4 ; Haukaas, Svein A. 5 ; Fasmer, Kristine E. 6 ; Haldorsen, Ingfrid H. S. 6 ; Beisland, Christian 7 ; Akslen, Lars A. 1 ; Halvorsen, Ole J. 8 

 University of Bergen, Centre for Cancer Biomarkers CCBIO, Gade Laboratory for Pathology, Department of Clinical Medicine, Bergen, Norway (GRID:grid.7914.b) (ISNI:0000 0004 1936 7443); Haukeland University Hospital, Department of Pathology, Bergen, Norway (GRID:grid.412008.f) (ISNI:0000 0000 9753 1393) 
 University of Bergen, Department of Clinical Medicine, Bergen, Norway (GRID:grid.7914.b) (ISNI:0000 0004 1936 7443); Haukeland University Hospital, Department of Radiology, Bergen, Norway (GRID:grid.412008.f) (ISNI:0000 0000 9753 1393) 
 Haukeland University Hospital, Department of Radiology, Bergen, Norway (GRID:grid.412008.f) (ISNI:0000 0000 9753 1393); Haukeland University Hospital, Mohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Bergen, Norway (GRID:grid.412008.f) (ISNI:0000 0000 9753 1393) 
 Haukeland University Hospital, Department of Pathology, Bergen, Norway (GRID:grid.412008.f) (ISNI:0000 0000 9753 1393) 
 Haukeland University Hospital, Department of Urology, Bergen, Norway (GRID:grid.412008.f) (ISNI:0000 0000 9753 1393) 
 University of Bergen, Department of Clinical Medicine, Bergen, Norway (GRID:grid.7914.b) (ISNI:0000 0004 1936 7443); Haukeland University Hospital, Mohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Bergen, Norway (GRID:grid.412008.f) (ISNI:0000 0000 9753 1393) 
 University of Bergen, Department of Clinical Medicine, Bergen, Norway (GRID:grid.7914.b) (ISNI:0000 0004 1936 7443); Haukeland University Hospital, Department of Urology, Bergen, Norway (GRID:grid.412008.f) (ISNI:0000 0000 9753 1393) 
 University of Bergen, Centre for Cancer Biomarkers CCBIO, Gade Laboratory for Pathology, Department of Clinical Medicine, Bergen, Norway (GRID:grid.7914.b) (ISNI:0000 0004 1936 7443) 
Pages
17949
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2879465740
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.